Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for HCW Biologics (HCWB) over the last 4 years, with Q3 2025 value amounting to 21095.26%.

  • HCW Biologics' EBITDA Margin fell 202312000.0% to 21095.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 2817.99%, marking a year-over-year decrease of 17572800.0%. This contributed to the annual value of 1148.5% for FY2024, which is 2435400.0% down from last year.
  • Latest data reveals that HCW Biologics reported EBITDA Margin of 21095.26% as of Q3 2025, which was down 202312000.0% from 52886.67% recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' EBITDA Margin registered a high of 60.33% during Q1 2022, and its lowest value of 52886.67% during Q2 2025.
  • Moreover, its 4-year median value for EBITDA Margin was 803.09% (2024), whereas its average is 8932.1%.
  • As far as peak fluctuations go, HCW Biologics' EBITDA Margin skyrocketed by 121338200bps in 2024, and later plummeted by -504408600bps in 2025.
  • Quarter analysis of 4 years shows HCW Biologics' EBITDA Margin stood at 422.45% in 2022, then crashed by -93bps to 813.31% in 2023, then rose by 1bps to 803.09% in 2024, then tumbled by -2527bps to 21095.26% in 2025.
  • Its last three reported values are 21095.26% in Q3 2025, 52886.67% for Q2 2025, and 38811.49% during Q1 2025.